Zacks Industry Outlook Highlights: BioScrip, Inc., WellPoint and NovaMed Inc.
2009-05-29 12:23:03 -
Zacks.com releases the latest Industry Outlook. Today’s interview is with senior analyst Chris Kallos, who talks about the Healthcare Industry, including BioScrip, Inc. ( BIOS : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. ), WellPoint ( WLP : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. ) and NovaMed Inc. ( NOVA : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. ).
A synopsis of today’s Industry Outlook is presented below. The full article can be read at at.zacks.com/?id=2678 : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fat. .. .
Health technology holds promise of improved operating efficiencies for many parts of the healthcare industry, hospitals included. However, in the short term those that stand to benefit the most from the stimulus are the companies whose business models are based on information technology platforms.
One such company is BioScrip, Inc. ( BIOS : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. ), a specialty pharmacy services provider and pharmacy benefit manager.
Bioscrip operates two interrelated business segments, namely: Specialty Services, which is comprised of specialty pharmacy distribution and clinical management services; and PBM Services, which is comprised of pharmacy benefit management and traditional mail services. We currently rate the stock of BioScrip a Buy.
Despite our currently neutral stance on managed care providers overall, we continue to rate WellPoint ( WLP : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. ) as a Buy given its broad product offering, geographic reach and potential for added synergy gains from relatively recent acquisitions.
That said, we believe the recent action by CMS to suspend the company from enrolling new patients in the health insurance Medicare Advantage plan and the prescription drug benefit, Medicare Part D will add to negative sentiment in the short term. We believe the action by CMS is reversible and highlights operational issues that can be addressed by management in the short term
Another current Buy recommendation is NovaMed Inc. ( NOVA : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww .. ).
NOVA is an emerging healthcare services company engaged in the operation of ambulatory surgery centers (ASCs) and the provision of optical products and services to eye-care professionals. We remain positive with the company's performance to date, given the continued strength of cash flows from operations and same facility revenue growth.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting at.zacks.com/?id=2679 : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fat. .. .
About Zacks
The performance of the Zacks Rank portfolios shown above for annual and year-to-date periods are the linked monthly total returns (price changes + dividends) of equal weighted hypothetical portfolios, consisting of those stocks with the indicated Zacks Rank, assuming monthly rebalancing and zero transaction costs. These are not the returns of actual portfolios. The hypothetical portfolios were created at the beginning of each month from Jan 1988 forward based on the values of the Zacks Rank available to Zacks' clients before the beginning of each month.
The portfolios created monthly from 1988 through September 2006 exclude ADRS and are comprised of stocks that have the indicated Zacks Rank and were covered by at least two analysts at the time of the stocks inclusion in the portfolio. Starting in October 2006 and going forward, the portfolios are comprised of all stocks with the indicated Zacks Rank and do not exclude ADRs, which is more reflective of the list of stocks that customers will find on the Zacks web sites. 2007 returns are for the period of Jan 1 – Jun 30, 2007. These performance numbers have been audited from 1995 through 2003 by Autschuler Melovan, a division of American Express Financial.
Zacks.comMark Vickery312-265-9380Visit: www.zacks.com : cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww ..
